Experts in dermatology emphasize the need to consider patients' overall well-being when evaluating the safety profiles of emerging biologic treatments for plaque psoriasis, taking into account the heightened levels of depression and anxiety in individuals with this condition.
George Han, MD, discusses the latest biologic agents for plaque psoriasis, addressing the balance between efficacy and speed of response. Together with Dr. Leon Kircik, they emphasize the significance of comprehensive data for physician confidence and delve into the clinical utilization of these treatments, stressing the importance of baseline laboratory measurements for all prescribed patients.
Leon Kircik, MD, emphasizes the combined use of emerging topical treatments with systemic or biologic medications and the impact of the treatment vehicle on penetration. He also discusses the potential for longer use of steroidal options by reducing active product quantities through better penetrating vehicles and highlights the potential heightened efficacy of newer topical treatments and the gaps they may fill in the management of this condition.
Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.
Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.
